{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:10Z","timestamp":1793656510508,"version":"4.5.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcyt.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:17:05Z","timestamp":1753456625000},"page":"1316-1325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus"],"prefix":"10.1016","volume":"27","author":[{"given":"Stefano","family":"Luminari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Di","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Freilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jcyt.2025.07.007_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jcyt.2025.07.007_bib0002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcyt.2025.07.007_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcyt.2025.07.007_bib0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jcyt.2025.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0006","unstructured":"National Cancer Institute. CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-brexucabtagene-mantle-cell-lymphoma#:\u223c:text=The%20new%20treatment%2C%20a%20CAR%20T-cell%20therapy%20called,B%20cells%2C%20a. (2020). [accessed 01.02.2025]."},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2025.07.007_bib0007","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2024-199139","article-title":"Real-world early outcomes of second-line axicabtagene ciloleucel (axi-cel) therapy in patients (pts) with relapsed or refractory (r\/r) large B-cell lymphoma (LBCL)","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2025.07.007_bib0008","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood-2024-209093","article-title":"Real-world trends of cytokine release syndrome and neurologic events, and pattern of their management among patients receiving axicabtagene ciloleucel for relapsed or refractory (r\/r) large B-cell lymphoma (LBCL) in the US: A CIBMTR Report","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.915342","article-title":"CAR T-cell therapies in Italy: patient access barriers and recommendations for health system solutions","volume":"13","author":"Jommi","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0010","article-title":"Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries","volume":"10","author":"Canales Albendea","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.jcyt.2025.07.007_bib0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2025.07.007_bib0012","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1182\/blood-2024-205589","article-title":"Estimating the impact on survival of not receiving CAR T therapy despite being eligible in relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) patients in Germany","volume":"144","author":"Buecklein","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0013","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1287\/mnsc.9.3.458","article-title":"An experimental application of the Delphi method to the use of experts","volume":"9","author":"Dalkey","year":"1963","journal-title":"Management Science"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0014","series-title":"The Delphi Method, Techniques and Applications","author":"Linstone","year":"1975"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0015","unstructured":"Ayyub BM. A Practical Guide on Conducting Expert-Opinion Elicitation of Probabilities and Consequences for Corps Facilities. IWR Report 01-R-01, Alexandria, VA, 2001."},{"issue":"11","key":"10.1016\/j.jcyt.2025.07.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.09.007","article-title":"Real-World analysis of barriers to timely administration of chimeric antigen receptor T cell (CAR T) therapy in diffuse large B-cell lymphoma","volume":"30","author":"Hu","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jcyt.2025.07.007_bib0017","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2025.07.007_bib0018","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00005650-199404000-00004","article-title":"Measuring the necessity of medical procedures","volume":"32","author":"Kahan","year":"1994","journal-title":"Med Care"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0019","series-title":"The RAND\/UCLA Appropriateness Method User's Manual","author":"Fitch","year":"2001"},{"issue":"11","key":"10.1016\/j.jcyt.2025.07.007_bib0020","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.jcyt.2025.07.007_bib0021","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jcyt.2025.07.007_bib0022","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.07.007_bib0023","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","article-title":"End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA","volume":"5","author":"Kostakoglu","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jcyt.2025.07.007_bib0024","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/bjh.20129","article-title":"Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline","volume":"206","author":"Chaganti","year":"2025","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jcyt.2025.07.007_bib0025","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.jcyt.2025.07.007_bib0026","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/bloodadvances.2024012760","article-title":"Defining primary refractory large B-cell lymphoma","volume":"8","author":"Bock","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jcyt.2025.07.007_bib0027","doi-asserted-by":"crossref","first-page":"e907","DOI":"10.1097\/HS9.0000000000000907","article-title":"Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed\/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use","volume":"7","author":"B\u00fccklein","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0028","unstructured":"Societ\u00e0 Italiana di Ematologia. Linee Guida SIE. https:\/\/www.siematologia.it\/linee-guida-sie.html (2023). [accessed 01.02.2025]."},{"issue":"5","key":"10.1016\/j.jcyt.2025.07.007_bib0029","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","article-title":"A multicenter real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in large B-cell lymphomas","volume":"5","author":"Stella","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"10.1016\/j.jcyt.2025.07.007_bib0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.jcyt.2025.07.007_bib0031","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!","volume":"132","author":"Dreyling","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jcyt.2025.07.007_bib0032","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.07.007_bib0033","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline","volume":"204","author":"Eyre","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.07.007_bib0034","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jcyt.2025.07.007_bib0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bjh.17363","article-title":"Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients","volume":"193","author":"McCulloch","year":"2021","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.jcyt.2025.07.007_bib0036","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/bloodadvances.2023009804","article-title":"Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/refractory mantle cell lymphoma","volume":"7","author":"Villa","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jcyt.2025.07.007_bib0037","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bjh.19961","article-title":"Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: results from CART-SIE study","volume":"206","author":"Stella","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.07.007_bib0038","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/10781552231216886","article-title":"Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma","volume":"30","author":"Davis","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.jcyt.2025.07.007_bib0039","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.07.007_bib0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0041","series-title":"Poster Presentation: P1159 EHA","article-title":"ZUMA-24 preliminary analysis: a phase 2 study of axicabtagene ciloleucel in the outpatient setting with prophylactic corticosteroids in patients with relapsed\/refractory large B-cell lymphoma","author":"Leslie","year":"2024"},{"issue":"11","key":"10.1016\/j.jcyt.2025.07.007_bib0042","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0043","series-title":"51st Congress of the Italian Society of Hematology","article-title":"The CARCHAT project and the Regione Lazio Lymphoma Network \u201cRELLI\u201d hub-and-spoke model for managing CAR-T patients journey","author":"Di Rocco","year":"2024"},{"key":"10.1016\/j.jcyt.2025.07.007_bib0044","series-title":"Poster ID number 6675676 presented at 7th EHA-EBMT European CAR T-cell Meeting","article-title":"CARe-Together: the first Italian Patient Support Program for CAR T patients","author":"Bramanti","year":"2025"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:09:28Z","timestamp":1772888968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925007881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1465324925007881"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.07.007","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}